Roche succeeds in late-stage study for Lunsumio regimen in follicular lymphoma
Hailshadow
Roche’s (RHHBY) Genentech unit on Thursday announced a late-stage trial success for a combination regimen containing its bispecific antibody, Lunsumio, against a hematological cancer known as follicular lymphoma.
The company said Lunsumio with lenalidomide, a cancer drug marketed by Bristol Myers (
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.